Targeting the MEK/ERK pathway is also not an effective long-term strategy against sorafenib resistance in RCC, because the activated c-MET will eventually lead to cell proliferation and metastasis through other pathway, such as TOPK/ERK, PRPK or PI3K/AKT [24, 34]. The gene discussed is MAPK1; the disease is renal cell carcinoma.